A Wonder Drug in the Arsenal against COVID - 19: Medication Evidence from Ivermectin

  • Kumar B
  • Jeyaraman M
  • Jain R
  • et al.
N/ACitations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Ivermectin, an FDA approved broad-spectrum anti-parasitic agent has been recently reported to show an inhibitory activity against SARS-CoV-2 in an in-vitro study. This antiviral response has rendered it as a potential drug to be repurposed for COVID-19. Previously, ivermectin had showed inhibitory activity against RNA viruses in-vitro and DNA viruses in-vitro and in-vivo respectively. Much of its characterization has been related to SARS-CoV wherein viral proteins interacting with IMPα/β1 (Importins) were proposed to enhance the viral infectivity. These documentations serve as a ray of hope for considering ivermectin in treating COVID-19 due to its suggested nuclear transport inhibitory mechanism. Importantly, these recent findings warrant detailed investigations for understanding its benefit in terms of efficacy and safety in COVID-19 patients. This review article throws light on the current consensus in this regard.

Cite

CITATION STYLE

APA

Kumar, B. S., Jeyaraman, M., Jain, R., & Anudeep, T. C. (2020). A Wonder Drug in the Arsenal against COVID - 19: Medication Evidence from Ivermectin. Journal of Advances in Medicine and Medical Research, 30–37. https://doi.org/10.9734/jammr/2020/v32i1030512

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free